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Percutaneous Retrograde Left Ventricular Assist Support for Patients With
Aortic Stenosis and Left Ventricular Dysfunction
Claudia A Martinez1, Vikas Singh1, Juan C Londono2, Mauricio G Cohen1, Carlos E
Alfonso1, William W O’Neill1, Alan W Heldman1
1University of Miami - Miller School of Medicine, Miami, FL; 2Mount Sinai Medical
Center, Miami, FL
Background: In preparation for transcatheter aortic valve implantation, an increasing
number of high-risk patients with severe AS and left ventricular dysfunction are
currently considered for percutaneous coronary interventions (PCI) and balloon aortic
valvuloplasty (BAV). Hemodynamic support may be required in some patients.
Methods: To evaluate feasibility and technical outcomes in patients with aortic stenosis
(AS) who have undergone high-risk procedures with continuous flow left ventricular
(LV) assist hemodynamic support, with the Impella 2.5 system (Abiomed Inc, Danvers,
Massachusetts).
Results: Over a 9-month period, 16 patients with AS underwent insertion of Impella
prior to high-risk PCI (n=3), BAV with subsequent PCI (n=5), BAV alone (n=5), or
during cardiac arrest immediately following BAV (n=3). The median Society of
Thoracic Surgeons (STS) predicted mortality risk was 13% (range 7.3% to 20.9%).
Impella was inserted successfully in all patients attempted. Retrograde advancement
of two catheters across the aortic valve (for concomitant BAV in 10 patients) was
technically feasible. Retrograde continuous flow LV assist produced a reduction in LV
end-diastolic pressure and an increase in arterial pressure. Periprocedural vascular
complications occurred in 3 patients, with no periprocedural deaths. Mortality at 30
days was 18.8%.
Conclusion: Our data suggests that continuous flow retrograde LV assist with Impella
2.5 is technically feasible in patients with severe AS and left ventricular dysfunction,
with favorable hemodynamics to support high risk interventions.
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Predictive value of EuroSCORE derived parameters for the development of
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Background: Postcardiotomy right ventricular (RV) failure is a well-known clinical
phenomenon, which is associated with an adverse prognosis. Nevertheless, limited
data are available on its predictors. The EuroSCORE is an established risk-prediction
model for mortality and in-hospital complications after cardiac surgery. The purpose
of our study was to investigate the predictive value of EuroSCORE-derived parameters
for the development of postcardiotomy RV failure. Although RV failure remains a
therapeutic challenge, a new percutaneous right ventricular assist devices has recently
become available. The early identification of patients in need for such support may
improve their prognosis.
Methods: A total of 1929 adult patients underwent cardiac surgery at our institution
from 2007 through 2009. Data on RV function and EuroSCORE parameters were
obtained through chart review. Right ventricular failure was defined as a tricuspid
annular plane systolic excursion (TAPSE) of ≤ 14 mm on echocardiography in patients
with a complicated postoperative course.
Results: Right ventricular failure occurred in 90/1929 (4.7%) patients. In 1898 patients,
EuroSCORE parameters were available for analysis. Independent predictors for the
development of RV failure included age >75, extracardiac arteriopathy, left ventricular
dysfunction, a critical preoperative state, creatinin level of >200 μmol, a recent
myocardial infarction, other than isolated coronary artery bypass grafting and
pulmonary hypertension. From these parameters, we constructed a simple risk score
for the preoperative prediction of development of postcardiotomy RV failure. The area
under the receiver-operating-characteristic curve was 0.81 (95% CI 0.77-0.86).
Conclusion: Postcardiotomy RV failure occurred in 4.7% of patients in a single-center
cohort of patients undergoing cardiac surgery. We developed a simple risk score based
on EuroSCORE-derived parameters to enable the preoperative identification of patients
at low, medium and high risk for developing postcardiotomy RV failure.
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Complete Revascularization Improves Survival in Patients with STEMI
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Background: Target-vessel (TV) percutaneous coronary intervention (PCI) is
recommended for patients with multivessel (MV) coronary disease presenting with
ST-segment elevation myocardial infarction (STEMI). However, guidelines suggest
that complete revascularization may be beneficial if STEMI is complicated by
cardiogenic shock. We sought to evaluate the role complete revascularization a high-
risk STEMI population.
Methods: We prospectively recruited consecutive STEMI patients with RCA arrest
and shock at 5 French tertiary referral centers. Cardiogenic shock was defined by a
blood pressure persistently <100/70mmHg. Multivessel disease was defined as ≥1
coronary stenosis (≥50%), and successful PCI by the restoration of thrombosis in
myocardial infarction (TIMI) III flow. The primary end-point was in-hospital mortality.
Results: In total, 162 patients (75.9% male) with a mean age of 59.9±13.7yrs were
recruited between March 2004-June 2010. Ventricular fibrillation was the underlying
arrhythmia in 66.1%, and the average time to defibrillation was 15.1±12.3 minutes. At
coronary angiography, at least 1 obstructive coronary lesion was present in all patients,
87.0% were ventilated, and 40.3% required intra-aortic balloon pump insertion. PCI
was deemed successful in 87.0%. In-hospital death occurred in 67.9% of cases.
Multivessel CAD was present in 56.2% (91) of patients. Of these, 62.3% (57)
underwent TV PCI only, and 37.7% (34) MV PCI. Patients undergoing MV PCI were
younger (60.4±12.5vs66.5±11.2,p=0.044), however other baseline characteristics were
similar between the groups. In the MV PCI cohort, on average 2.2±0.3 coronary arteries
were treated. In-hospital mortality was significantly decreased in patients who had MV
PCI compared to those who has TV PCI only (47.1%vs80.7%,p=0.01).
Conclusion: This is the first study to demonstrate that MV PCI may improve outcomes
in patients presenting with STEMI, complicated by RCA and shock. Further
prospective studies are required to confirm these results.
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Background: Cardiogenic shock (CS) following acute myocardial infarction (AMI)
is associated with high in-hospital mortality rates and many patients succumb to
persisting low cardiac output and multiple organ failure. Percutaneous left ventricular
assist devices (pLVAD) provide circulatory support by replacing LV function to bridge
potentially recoverable heart failure. The purpose of the Impella EUROSHOCK-
registry was to evaluate the safety and efficacy of the Impella-2.5 (Abiomed Europe,
Germany) in patients with severe CS after AMI in contemporary practice.
Methods: The registry retrospectively included 120 (mean age 63.6±12.2; male 81.7%)
patients in CS with AMI from 14 institutions across Europe who received temporary
circulatory support with the Impella-2.5-pLVAD. Data were collected by standardized
case report forms. The primary outcome was overall mortality at 30 days, the secondary
outcome was the change of plasma lactate levels and MACE. Multivariate logistic
regression analysis was performed to identify independent predictors of outcome.
Results: Overall 30-day mortality was 64.2%. After placing an Impella 2.5, lactate
levels decreased significantly from 5.8±5.0mmol/l to 4.7±5.4mmol/l at 24 hours and
to 2.5±2.6mmol/l at 48 hours (p=0.003). Age>65 and plasma lactate levels upon
hospital admission >3.8mmol/l were significant predictors of 30day-mortality. Long-
term survival after a follow-up period of 317±526 days was 28.3%. Major cardiac and
cerebral events were reported in 18 (15%) patients. Rates of bleeding requiring
transfusion and/or surgery occurred in 34(28.6%), haemolysis in 9(7.5%) and
pericardial tamponade in 2(1.7%) patients.
Conclusion: In AMI patients with CS, Impella 2.5-treatment is feasible and resulted
in a reduction of lactate levels. Overall 30-day mortality was high, reflecting the last-
resort character of Impella treatment and the selection of patients with a particularly
poor hemodynamic profile and a greater imminent risk of death. Further studies and
adequately powered controlled trials are necessary to investigate the efficacy of Impella
2.5 support in AMI patients with CS.
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